{
 "metadata": {
  "name": "",
  "signature": "sha256:2b78d923a12642587d30600958aad7a12ca86b2a3f971dc3055b6f3ada242d21"
 },
 "nbformat": 3,
 "nbformat_minor": 0,
 "worksheets": [
  {
   "cells": [
    {
     "cell_type": "heading",
     "level": 2,
     "metadata": {},
     "source": [
      "Agreement with EU-ADR for job 716713"
     ]
    },
    {
     "cell_type": "markdown",
     "metadata": {},
     "source": [
      "2015-04-22 Tong Shu Li"
     ]
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "import pandas as pd\n",
      "import matplotlib.pyplot as plt\n",
      "\n",
      "%matplotlib inline\n",
      "%pylab inline"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "Populating the interactive namespace from numpy and matplotlib\n"
       ]
      }
     ],
     "prompt_number": 1
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "from itertools import islice"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 2
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "import sys\n",
      "sys.path.append(\"/home/toby/crowdsourcing/drug_disease_semantics/src/\")\n",
      "\n",
      "from filter_data import filter_data\n",
      "from aggregate_results import aggregate_results\n",
      "from true_relation_type import get_euadr_relation_type\n",
      "from get_orig_problem import get_orig_problem"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 3
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "sys.path.append(\"/home/toby/global_util/\")\n",
      "from file_util import read_file"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 4
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "settings = {\n",
      "    \"loc\": \"/home/toby/crowdsourcing/drug_disease_semantics/data/\",\n",
      "    \"fname\": \"job_716713_full_with_untrusted_and_unfinished.tsv\",\n",
      "    \"data_subset\": \"normal\",\n",
      "    \"min_accuracy\": 0.7,\n",
      "    \"max_accuracy\": 1.0,\n",
      "    \"id_column\": \"pub_rel_id\"\n",
      "}"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 5
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "raw_data = filter_data(settings)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 6
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "euadr_answer = get_euadr_relation_type(settings)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 7
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "len(raw_data)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "metadata": {},
       "output_type": "pyout",
       "prompt_number": 8,
       "text": [
        "1022"
       ]
      }
     ],
     "prompt_number": 8
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "def create_match(gold_std_answer):\n",
      "    def match(identifier, crowd_choice):\n",
      "        return int(crowd_choice == gold_std_answer[identifier])\n",
      "    \n",
      "    return match"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 9
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "match_obj = create_match(euadr_answer)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 10
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "results = aggregate_results(\"pub_rel_id\", \"broad_rel_type\", raw_data, match_obj)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 11
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "def determine_matches(results):\n",
      "    matches = []\n",
      "    mismatches = []\n",
      "    for rel_id, group in results.groupby(\"pub_rel_id\"):\n",
      "        if group.iloc[0][\"match\"] == 1:\n",
      "            matches.append(rel_id)\n",
      "        else:\n",
      "            mismatches.append(rel_id)\n",
      "            \n",
      "    return (matches, mismatches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 12
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "matches, mismatches = determine_matches(results)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 13
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "def broad_reltype_summary(settings):\n",
      "    raw_data = filter_data(settings)\n",
      "\n",
      "    true_relation_type = get_euadr_relation_type(settings)\n",
      "\n",
      "    match_obj = create_match(true_relation_type)\n",
      "\n",
      "    results = aggregate_results(\"pub_rel_id\", \"broad_rel_type\", raw_data, match_obj)\n",
      "\n",
      "#--------------------------------------------------------------------\n",
      "    ans = pd.Series([0] * 4)\n",
      "    for unit_id, group in results.groupby(settings[\"id_column\"]):\n",
      "        temp = list(group[\"match\"])\n",
      "        ans = ans.add(pd.Series(temp), fill_value = 0)\n",
      "\n",
      "    num_work_units = len(results[settings[\"id_column\"]].unique())\n",
      "\n",
      "    print \"Distribution of matches with gold standard based on response rank:\\n{0}\".format(ans)\n",
      "    print\n",
      "    print (\"Total number of work units for this subset of data: {0}\".\n",
      "        format(num_work_units))\n",
      "    print\n",
      "    print \"Number of correct responses with respect to the rank of confidence score:\"\n",
      "    print (\"{0}/{1} ({2}%) work units had the correct answer in the top ranked position\".\n",
      "           format(ans[0], num_work_units, ans[0]/num_work_units * 100))\n",
      "\n",
      "    graph = ans.plot(kind = \"bar\")\n",
      "    graph.set_xlabel(\"Rank of the correct choice according to the crowd\")\n",
      "    graph.set_ylabel(\"Number of work units where the crowd chosen top answer\\n\"\\\n",
      "        \"matched that of the gold standard\")"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 14
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "broad_reltype_summary(settings)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "Distribution of matches with gold standard based on response rank:\n",
        "0    165\n",
        "1     24\n",
        "2      4\n",
        "3      0\n",
        "dtype: float64\n",
        "\n",
        "Total number of work units for this subset of data: 244\n",
        "\n",
        "Number of correct responses with respect to the rank of confidence score:\n",
        "165.0/244 (67.6229508197%) work units had the correct answer in the top ranked position\n"
       ]
      },
      {
       "metadata": {},
       "output_type": "display_data",
       "png": "iVBORw0KGgoAAAANSUhEUgAAAY0AAAExCAYAAACAr/7fAAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\n",
       "text": [
        "<matplotlib.figure.Figure at 0x7fb5af469bd0>"
       ]
      }
     ],
     "prompt_number": 15
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "orig_problem = get_orig_problem(\"pub_rel_id\", raw_data)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 16
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "def sort_by_conf(work_units):\n",
      "    \"\"\"\n",
      "    Sort the work units in decreasing order of agreement\n",
      "    for the top chosen crowd answer.\n",
      "    \"\"\"\n",
      "    temp = []\n",
      "    for rel_id in work_units:\n",
      "        group = results.query(\"pub_rel_id == '{0}'\".format(rel_id))\n",
      "        temp.append((rel_id, group.iloc[0][\"percent_agree\"]))\n",
      "        \n",
      "    temp = sorted(temp, key = lambda x: x[1], reverse = True)\n",
      "    return [val[0] for val in temp]"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 17
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "matches = sort_by_conf(matches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 18
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "mismatches = sort_by_conf(mismatches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 19
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "loc = \"/home/toby/crowdsourcing/drug_disease_semantics/data/\"\n",
      "\n",
      "pub_to_raw_mapping = dict()\n",
      "for line in islice(read_file(loc + \"raw_to_toby_mapping.txt\"), 1, None):\n",
      "    pub_rel_id, raw_rel_id, num_agree = line.split('|')\n",
      "    pub_to_raw_mapping[pub_rel_id] = (raw_rel_id, int(num_agree))"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 20
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "def summary(work_units):\n",
      "    for identifier in work_units:\n",
      "        subset = results.query(\"pub_rel_id == '{0}'\".format(identifier))\n",
      "        \n",
      "        unit_id = raw_data.query(\"pub_rel_id == '{0}'\".format(identifier)).iloc[0][\"_unit_id\"]\n",
      "        \n",
      "        print \"Unit id: {0}\".format(unit_id)\n",
      "        print\n",
      "        print \"EU-ADR answer:\", euadr_answer[identifier]\n",
      "        print \"Experts agree: {0}/3\".format(pub_to_raw_mapping[identifier][1])\n",
      "        print\n",
      "        print subset\n",
      "        print\n",
      "        print orig_problem[identifier][3]\n",
      "        print\n",
      "        print \"============================================================\""
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 21
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "summary(mismatches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "Unit id: 706124689\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "       pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_1       positive      2.4251          3              1      0\n",
        "\n",
        "[[Cardiovascular thromboembolic adverse effects]] associated with [[cyclooxygenase]]-2 selective inhibitors and nonselective antiinflammatory drugs.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707779908\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_116       positive        2.85          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "[[Long-term immunomodulatory drug]] (IMD) treatment is now common in [[multiple sclerosis]] (MS).\n",
        "\n",
        "============================================================\n",
        "Unit id: 707780025\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_119       negative      2.5126          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "In ER+ breast tumors, 2.5 mg/d [[tibolone]] given for 14 days has no significant effect on [[tumor]] cell proliferation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124819\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 1/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_121    speculative      2.4848          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "Exposure to Benzodiazepines ([[BZD]]) during foetal life has been suggested to contribute to neonatal morbidity and some [[congenital malformations]], for example, orofacial clefts.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124752\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_122    speculative       2.397          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "Exposure to [[Benzodiazepines]] (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, [[orofacial clefts]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124900\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_124       positive        2.85          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "Maternal use of [[BZD]] and/or HBRA may increase the risk for [[preterm birth]] and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124921\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_129       positive      2.5421          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "After two years [[ecstasy]] users showed persistent [[deficits on verbal fluency]], working memory and processing speed.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124922\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_130       positive      2.6836          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "When ecstasy users were classified according to lifetime use of [[ecstasy]], the more severe users (more than 100 tablets) showed additional [[deficits on episodic memory]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124800\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_135       positive      2.5666          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with [[chronic hepatitis C genotype 4]] treated with [[peginterferon]] plus ribavirin.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124705\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_140       positive      2.4892          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "Women exposed to [[radioisotopes]] experienced at least a threefold higher rate of [[spontaneous abortions]] than those exposed to X-ray (OR = 3.68, 95% CI = 1.39-9.74, P < 0.01).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124914\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_162       positive      2.3596          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "There was an estimated 50% excess risk of [[malignancy]] among [[methotrexate]]-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124866\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_17       positive      2.5421          3              1      0\n",
        "\n",
        "This article reviewed recent results from randomized, double-blind studies of children with [[mild asthma]] treated with [[montelukast]], a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124903\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_171       positive      2.4833          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "[[Recombinant hirudin]] is used as an alternative anticoagulant, particularly in patients with [[heparin-induced thrombocytopenia type II]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124725\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_174       positive       2.397          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "Children with prosthetic cardiac valves and other invasive mechanical devices that direct blood flow require [[anticoagulant]] medication for prevention of [[thrombosis]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124864\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_182       negative      2.3596          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "This once-weekly regimen is generally well tolerated, and studies to date have reported that [[epoetin beta]] has a neutral effect on survival of patients with [[cancer]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124862"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_199       negative      2.6092          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "Compared with both diuretics and contemporary agents, [[amlodipine]] decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or [[cancer]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124872\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "       pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_2       positive      2.5421          3              1      0\n",
        "\n",
        "[[Cardiovascular thromboembolic adverse effects]] associated with cyclooxygenase-2 selective inhibitors and [[nonselective antiinflammatory drugs]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124824\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_219       positive      2.5873          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "The established [[teratogenicity]] of [[antiepileptic drugs]] raises important issues in women of child-bearing age.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124867\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_227       positive      2.6836          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "Two years after initiating [[SRL]], she presented complaints of progressive dyspnoea, [[nonproductive cough]], chest pain and low-grade fever of 1 month duration.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124718\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_228       positive      2.4892          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "Two years after initiating [[SRL]], she presented complaints of progressive dyspnoea, nonproductive cough, [[chest pain]] and low-grade fever of 1 month duration.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124708\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_229       positive      2.6209          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "The only patient with [[leucoencephalopathy]] showed improved neurologic status after [[SRL]] conversion.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124896\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_233       positive        2.85          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), [[gastrointestinal]] (GI) side effects of [[mycophenolate mofetil]] (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124741\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_237    speculative      2.7424          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Furthermore, the efficacy of the new generation of [[antiepileptic agents]] in the prophylaxis of [[perioperative seizures]] has not been assessed so far.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124784\n",
        "\n",
        "EU-ADR answer: speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_238       positive      2.4745          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "We tested the hypothesis that [[oral beclomethasone dipropionate]] (BDP) would control gastrointestinal graft-versus-host disease ([[GVHD]]) in patients with anorexia, vomiting, and diarrhea.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124790\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_239       positive      2.4745          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "We tested the hypothesis that oral beclomethasone dipropionate ([[BDP]]) would control [[gastrointestinal graft-versus-host disease]] (GVHD) in patients with anorexia, vomiting, and diarrhea.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707284767\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_54       positive       2.609          3              1      0\n",
        "\n",
        "Past use of [[antimetabolites]], T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 [[ocular inflammation]] patients at five tertiary centers over up to 30 years.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124920\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_58       positive      2.6092          3              1      0\n",
        "\n",
        "Past use of antimetabolites, [[T-cell inhibitors]], alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 [[ocular inflammation]] patients at five tertiary centers over up to 30 years.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124690\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_67       positive      3.5426          4              1      0\n",
        "\n",
        "An inverse trend was observed between dose and multiplicity of [[colonic dysplasias]] in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/[[DSS]] controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124834\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_75       positive      2.5598          3              1      0\n",
        "\n",
        "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of [[azoxymethane]] (AOM)/dextran sulfate sodium (DSS)-induced [[colitis-associated neoplasia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124711\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_76       positive      2.7424          3              1      0\n",
        "\n",
        "Administration of 75 mg/kg [[5-ASA]] decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of [[polypoid dysplasias]] (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124745\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_80       positive      2.6322          3              1      0"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium ([[DSS]])-induced [[colitis-associated neoplasia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124685\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_87       positive      2.6209          3              1      0\n",
        "\n",
        "Development of [[sarcoidosis]] in [[etanercept]]-treated rheumatoid arthritis patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124909\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_88       positive      2.4148          3              1      0\n",
        "\n",
        "Development of sarcoidosis in [[etanercept]]-treated [[rheumatoid arthritis]] patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706988916\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_91       positive      2.5421          3              1      0\n",
        "\n",
        "[[BiRD]] (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic [[multiple myeloma]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124865\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_92       positive      2.5879          3              1      0\n",
        "\n",
        "This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone ([[BiRD]]) as first-line therapy for [[multiple myeloma]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124729\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_86       positive      4.1326          5       0.830723      0\n",
        "1  drug_disease_86    speculative      0.8421          1       0.169277      0\n",
        "\n",
        "Recently, there have been reports of [[noninfectious granulomatous syndromes]] in patients receiving [[etanercept]] for a variety of diseases.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124838\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_235       positive      3.4438          4        0.81149   \n",
        "0  drug_disease_235          false      0.8000          1        0.18851   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "0      1  \n",
        "\n",
        "Our data showed that oxcarbazepine can be a good alternative to traditional [[antiepileptic agents]] in the prevention of [[perioperative seizures]] being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124750\n",
        "\n",
        "EU-ADR answer: speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_107       positive      2.6532          3       0.779619   \n",
        "1  drug_disease_107    speculative      0.7500          1       0.220381   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "1      1  \n",
        "\n",
        "At this time, [[posaconazole]] should probably be reserved for prophylaxis in patients at high risk for invasive fungal infection, as salvage therapy in refractory or [[resistant infections]], or for patients with intolerance to other therapies.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124746"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "       pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_9       positive      2.7655          3       0.775628      0\n",
        "0  drug_disease_9          false      0.8000          1       0.224372      1\n",
        "\n",
        "Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A ([[CsA]])-induced [[gingival overgrowth]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124717\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_132       negative      2.5025          3       0.774816   \n",
        "1  drug_disease_132    speculative      0.7273          1       0.225184   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "1      0  \n",
        "\n",
        "No significant differences were observed between FeSO4+citrate and [[NaFe-EDTA]] fortification, regarding mitigation of [[iron-deficiency anemia]] (IDA) or regarding CRP, growth, infections, or side-effects.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707286745\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_203       negative      2.7947          3       0.770314   \n",
        "0  drug_disease_203          false      0.8333          1       0.229686   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "0      1  \n",
        "\n",
        "Compared with both diuretics and contemporary agents, [[amlodipine]] decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, [[gastrointestinal bleeding]] or cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124754\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_120       negative      2.5509          3        0.76832   \n",
        "1  drug_disease_120       positive      0.7692          1        0.23168   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "1      0  \n",
        "\n",
        "In [[ER+ breast tumors]], 2.5 mg/d [[tibolone]] given for 14 days has no significant effect on tumor cell proliferation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124842\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_143       positive      2.5901          3       0.764019   \n",
        "0  drug_disease_143          false      0.8000          1       0.235981   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "0      1  \n",
        "\n",
        "Primary outcomes were [[asthma exacerbations]] (AE) requiring systemic [[corticosteroids]] or hospitalization, life-threatening exacerbations and asthma-related deaths.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124743\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_16       positive      2.6083          3       0.763554      0\n",
        "1  drug_disease_16    speculative      0.8077          1       0.236446      0\n",
        "\n",
        "Review of recent results of [[montelukast]] use as a monotherapy in children with [[mild asthma]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124833\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_89       positive      2.3743          3       0.763171      0\n",
        "0  drug_disease_89          false      0.7368          1       0.236829      1\n",
        "\n",
        "The other developed [[erythema nodosum]] and a plaque lesion on the right arm after 1 year of [[etanercept]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124898\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_57       positive      2.5515          3       0.759556      0\n",
        "1  drug_disease_57    speculative      0.8077          1       0.240444      0"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Past use of antimetabolites, T-cell inhibitors, [[alkylating agents]], and other immunosuppressives is ascertained from medical records of approximately 9,250 [[ocular inflammation]] patients at five tertiary centers over up to 30 years.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124888\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_134       negative      2.7515          3       0.750095   \n",
        "1  drug_disease_134       positive      0.9167          1       0.249905   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "1      0  \n",
        "\n",
        "No significant differences were observed between [[FeSO4]]+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, [[infections]], or side-effects.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124873\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_198       positive      2.7189          3       0.749421   \n",
        "0  drug_disease_198          false      0.9091          1       0.250579   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "0      1  \n",
        "\n",
        "Long-term exposure to [[medium-dose glucocorticoid]] therapy associates with hypertension in patients with [[rheumatoid arthritis]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124832\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_133       negative      2.4848          3       0.748862   \n",
        "1  drug_disease_133       positive      0.8333          1       0.251138   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "1      0  \n",
        "\n",
        "No significant differences were observed between [[FeSO4]]+citrate and NaFe-EDTA fortification, regarding mitigation of [[iron-deficiency anemia]] (IDA) or regarding CRP, growth, infections, or side-effects.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124699\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_94       positive      2.4559          3       0.746656      0\n",
        "1  drug_disease_94    speculative      0.8333          1       0.253344      0\n",
        "\n",
        "Recent prospective studies from Europe suggest the use of intracameral [[antibiotics]] for prophylaxis of [[endophthalmitis]], although the studies did not make a comparison with the most common United States prophylaxis techniques.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124818\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_232       positive      2.2778          3       0.732153   \n",
        "0  drug_disease_232          false      0.8333          1       0.267847   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "0      1  \n",
        "\n",
        "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), [[gastrointestinal]] (GI) side effects of mycophenolate mofetil ([[MMF]]; n = 5; 15%), and hyperglycemia (n = 4; 12%).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124695\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_61       positive      2.4670          3       0.727707      0\n",
        "0  drug_disease_61          false      0.9231          1       0.272293      1\n",
        "\n",
        "Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other [[immunosuppressives]] is ascertained from medical records of approximately 9,250 [[ocular inflammation]] patients at five tertiary centers over up to 30 years.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124808\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_200       positive      4.1553          5        0.72621   \n",
        "1  drug_disease_200    speculative      1.5666          2        0.27379   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "1      0  \n",
        "\n",
        "[[Dihydropyridine calcium channel antagonists]] may exert effects that protect against [[stroke]] that are independent of their blood pressure-lowering mechanism.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124886"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_152       negative      4.2158          5       0.724004   \n",
        "1  drug_disease_152       positive      1.6071          2       0.275996   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "1      1  \n",
        "\n",
        "The study showed that ziprasidone was effective and tolerable, that use of [[ziprasidone]] was characterized by an absence of [[extrapyramidal symptoms]] and weight gain, and that no alterations in clinical laboratory tests occurred.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124905\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_44       negative      2.4148          3       0.718862      0\n",
        "0  drug_disease_44          false      0.9444          1       0.281138      0\n",
        "\n",
        "Interestingly, 5 microM of [[indomethacin-loaded nanocapsules]] was able to cause an antiproliferative effect without promoting necrosis in [[glioma]] cells.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124810\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_60       positive      4.2496          5       0.718299      0\n",
        "0  drug_disease_60          false      0.8333          1       0.140851      1\n",
        "2  drug_disease_60    speculative      0.8333          1       0.140851      0\n",
        "\n",
        "Information from the SITE Cohort Study should clarify whether use of these [[immunosuppressive drugs]] for [[ocular inflammation]] increases the risk of mortality and fatal cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124691\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_138       positive      2.3606          3       0.717682   \n",
        "1  drug_disease_138    speculative      0.9286          1       0.282318   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "1      0  \n",
        "\n",
        "Exposure to [[radioisotopes of metals and halogen elements]] occurring in medical practice may cause [[spontaneous abortions]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124703\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_31    speculative      2.3042          3       0.712757      0\n",
        "0  drug_disease_31          false      0.9286          1       0.287243      1\n",
        "\n",
        "The aim of this study was to evaluate the effects of [[indomethacin-loaded nanocapsules]] and indomethacin ethyl ester-loaded nanocapsules on [[glioma]] cell lines.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707131026\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_18          false      4.0003          5       0.711886      0\n",
        "1  drug_disease_18       negative      1.6190          2       0.288114      0\n",
        "\n",
        "A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, [[montelukast]], leukotriene receptor antagonist, pediatric asthma, [[mild asthma]], exercise-induced asthma, and bronchoconstriction.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124781\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_183       positive      2.3166          3       0.711093   \n",
        "1  drug_disease_183    speculative      0.9412          1       0.288907   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "1      0  \n",
        "\n",
        "[[Epoetin beta]] once weekly: review of its efficacy and safety in patients with chemotherapy-induced [[anemia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124680\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_190    speculative      4.4341          5       0.707611   \n",
        "0  drug_disease_190       positive      1.8322          2       0.292389   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "0      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "[[Zidovudine]] discontinuation could help to avoid [[anaemia]] associated with anti-HCV therapy.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706987913\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_125    speculative      1.7500          2       0.704707   \n",
        "0  drug_disease_125       positive      0.7333          1       0.295293   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "0      0  \n",
        "\n",
        "Exposure to Benzodiazepines ([[BZD]]) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, [[orofacial clefts]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124751\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_123    speculative      4.0229          5       0.703895   \n",
        "0  drug_disease_123       positive      1.6923          2       0.296105   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "0      0  \n",
        "\n",
        "Exposure to [[Benzodiazepines]] (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some [[congenital malformations]], for example, orofacial clefts.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124876\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_41    speculative      1.7333          2       0.697983      0\n",
        "0  drug_disease_41       positive      0.7500          1       0.302017      1\n",
        "\n",
        "The aim of this study was to evaluate the effects of indomethacin-loaded nanocapsules and [[indomethacin ethyl ester-loaded nanocapsules]] on [[glioma]] cell lines.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124724\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "2  drug_disease_40    speculative      4.9799          6       0.669359      0\n",
        "1  drug_disease_40       positive      1.6364          2       0.219952      1\n",
        "0  drug_disease_40          false      0.8235          1       0.110688      0\n",
        "\n",
        "Further investigations using in vivo [[glioma]] model should be helpful to confirm the distinct effects of indomethacin-loaded nanocapsules and [[indomethacin ethyl ester-loaded nanocapsules]], in normal versus tumoral cells.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124839\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_109          false      4.6922          6       0.640678   \n",
        "1  drug_disease_109       positive      2.6316          3       0.359322   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "1      1  \n",
        "\n",
        "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and [[aspergillosis]] (CI not reported, p < 0.001) when compared with [[fluconazole]] and itraconazole in neutropenic patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124753\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "2  drug_disease_131       positive      4.3622          5       0.575974   \n",
        "1  drug_disease_131       negative      2.2781          3       0.300795   \n",
        "0  drug_disease_131          false      0.9333          1       0.123231   \n",
        "\n",
        "   match  \n",
        "2      0  \n",
        "1      0  \n",
        "0      1  \n",
        "\n",
        "No significant differences were observed between FeSO4+citrate and [[NaFe-EDTA]] fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, [[infections]], or side-effects.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124693\n",
        "\n",
        "EU-ADR answer: speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_49       positive      4.2978          5       0.567996      0\n",
        "1  drug_disease_49    speculative      3.2688          4       0.432004      1\n",
        "\n",
        "Available studies in the literature using clozapine in the pediatric population are summarized and the NIMH experience in treating [[refractory childhood-onset schizophrenia]] cases with [[clozapine]] is discussed.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124801"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_202       negative      4.2201          5       0.565545   \n",
        "2  drug_disease_202       positive      2.5086          3       0.336183   \n",
        "0  drug_disease_202          false      0.7333          1       0.098271   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "2      0  \n",
        "0      1  \n",
        "\n",
        "Compared with both diuretics and contemporary agents, [[amlodipine]] decreases cardiovascular events to a similar or greater extent without evidence for increased [[coronary heart disease]], gastrointestinal bleeding or cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124788\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "2  drug_disease_173       positive      4.0853          5       0.559569   \n",
        "3  drug_disease_173    speculative      1.4666          2       0.200882   \n",
        "0  drug_disease_173          false      0.9412          1       0.128917   \n",
        "1  drug_disease_173       negative      0.8077          1       0.110632   \n",
        "\n",
        "   match  \n",
        "2      0  \n",
        "3      0  \n",
        "0      1  \n",
        "1      0  \n",
        "\n",
        "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral [[anticoagulant]] and instituting heparin therapy prior to the planned dental procedure, which can result in [[thromboembolism]] and increased morbidity and mortality.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124878\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "2  drug_disease_66       positive      4.0681          5       0.555941      0\n",
        "0  drug_disease_66          false      2.4312          3       0.332245      1\n",
        "1  drug_disease_66       negative      0.8182          1       0.111814      0\n",
        "\n",
        "An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of [[dysplasias]] of the AOM/[[DSS]] controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124826\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_205       positive      4.1216          5       0.555846   \n",
        "1  drug_disease_205    speculative      3.2934          4       0.444154   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "1      0  \n",
        "\n",
        "[[Dihydropyridine calcium channel antagonists]] have several noteworthy attributes that merit consideration in the management of [[hypertension]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124823\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "       pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_3       negative      4.1062          5       0.553009      0\n",
        "0  drug_disease_3          false      3.3190          4       0.446991      1\n",
        "\n",
        "The frequency of PONV did not correlate to the amounts of [[alfentanil]], propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or [[motion sickness]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124749\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_68       positive      4.1262          5       0.531166      0\n",
        "0  drug_disease_68          false      3.6420          4       0.468834      1\n",
        "\n",
        "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of [[azoxymethane]]/dextran sulfate sodium-induced [[colitis]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124875\n",
        "\n",
        "EU-ADR answer: speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_106       positive      3.4386          4       0.465512   \n",
        "2  drug_disease_106    speculative      3.1624          4       0.428121   \n",
        "0  drug_disease_106       negative      0.7857          1       0.106367   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "2      1  \n",
        "0      0  \n",
        "\n",
        "At this time, [[posaconazole]] should probably be reserved for prophylaxis in patients at high risk for [[invasive fungal infection]], as salvage therapy in refractory or resistant infections, or for patients with intolerance to other therapies.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124722"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "       pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_4       negative      3.4528          4       0.452565      0\n",
        "0  drug_disease_4          false      3.3195          4       0.435093      1\n",
        "2  drug_disease_4       positive      0.8571          1       0.112342      0\n",
        "\n",
        "The frequency of PONV did not correlate to the amounts of alfentanil, [[propofol]], postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or [[motion sickness]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124712\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_223          false      3.2879          4       0.447863   \n",
        "3  drug_disease_223    speculative      1.7693          2       0.241006   \n",
        "2  drug_disease_223       positive      1.5508          2       0.211243   \n",
        "1  drug_disease_223       negative      0.7333          1       0.099887   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "3      0  \n",
        "2      1  \n",
        "1      0  \n",
        "\n",
        "Data of our study revealed an unexpected high rate of hypogonadism irrespective of [[cyclophosphamide]] use, and subclinical involvement of the testes by the [[vasculitis]] itself might be an alternative explanation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124813\n",
        "\n",
        "EU-ADR answer: negative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "2  drug_disease_222       positive      3.2548          4       0.444414   \n",
        "1  drug_disease_222       negative      2.5113          3       0.342896   \n",
        "0  drug_disease_222          false      0.8077          1       0.110284   \n",
        "3  drug_disease_222    speculative      0.7500          1       0.102406   \n",
        "\n",
        "   match  \n",
        "2      0  \n",
        "1      1  \n",
        "0      0  \n",
        "3      0  \n",
        "\n",
        "Data of our study revealed an unexpected high rate of [[hypogonadism]] irrespective of [[cyclophosphamide]] use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124868\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "2  drug_disease_45    speculative      3.1956          4       0.443421      0\n",
        "1  drug_disease_45       positive      3.1929          4       0.443046      1\n",
        "0  drug_disease_45       negative      0.8182          1       0.113533      0\n",
        "\n",
        "Further investigations using in vivo [[glioma]] model should be helpful to confirm the distinct effects of [[indomethacin-loaded nanocapsules]] and indomethacin ethyl ester-loaded nanocapsules, in normal versus tumoral cells.\n",
        "\n",
        "============================================================\n"
       ]
      }
     ],
     "prompt_number": 22
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "summary(matches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "Unit id: 706124714\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "       pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_0       positive      2.5589          3              1      1\n",
        "\n",
        "Body height, weight and obesity increase the risk of [[venous thrombosis]], especially obesity in women using [[oral contraceptives]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124787\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_101       positive      2.3788          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "The most common adverse effects associated with the use of [[posaconazole]] include headache, fever, [[nausea]], vomiting, and diarrhea.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124869\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_102       positive      2.5879          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "The most common adverse effects associated with the use of [[posaconazole]] include headache, fever, nausea, [[vomiting]], and diarrhea.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124890\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_104       positive      2.6092          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Similarly, the same regimen of [[posaconazole]] reduced [[invasive fungal infections]] (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124830\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_110       positive      2.3788          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "[[Posaconazole]], in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and [[aspergillosis]] incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124885\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_112       positive      2.5879          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Posaconazole is noninferior to [[fluconazole]] for treatment of [[oropharyngeal candidiasis]] (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124821"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_113       positive      2.4848          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough [[invasive fungal infections]] (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving [[fluconazole]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124836\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_118       positive      2.4745          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "[[Tibolone]] is a selective tissue estrogenic activity regulator, approved for the treatment of [[vasomotor symptoms]] in postmenopausal women.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124702\n",
        "\n",
        "EU-ADR answer: negative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_126       negative       2.397          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "We found no evidence of impaired control of the carbohydrate and lipid metabolism or aggravation of [[vascular lesions]] during the two years an [[etonogestrel]] implant was used by diabetic women.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707282367\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_13          false      2.3596          3              1      1\n",
        "\n",
        "Gingival samples were collected from eight normal healthy individuals, eight patients with [[periodontitis]], and eight patients with cyclosporin A ([[CsA]])-induced gingival overgrowth.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124785\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_136       positive      2.5078          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Adverse events were similar across treatment groups except for higher rates of [[anemia]] in the groups receiving [[ribavirin]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124764\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_137       positive      2.5078          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with [[chronic hepatitis C genotype 4]] treated with peginterferon plus [[ribavirin]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124688\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_14       positive      2.4221          3              1      1\n",
        "\n",
        "Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with [[cyclosporin A]] (CsA)-induced [[gingival overgrowth]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124719\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_141       positive      2.6754          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "An open multicenter phase II trial of weekly [[docetaxel]] for [[advanced-stage non-small-cell lung cancer]] in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124882"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_142       positive      2.4148          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Contrarily, [[LABA]] showed a significant increase in [[asthma-related deaths]] (Relative Risk=3.83; 95% CI, 1.21-12.14).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124765\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_144       positive      2.4245          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of [[high-dose cyclophosphamide]] 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124812\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_145       positive      2.5873          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, [[adriamycin]] 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124829\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_146       positive      2.5598          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, [[cisplatin]], cytarabine and prednisone.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124820\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_147       positive      2.5873          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and [[prednisone]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707287260\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_150       positive        2.85          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of [[etoposide]], cisplatin, cytarabine and prednisone.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124740\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_151       positive       2.397          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Plasma [[ziprasidone]] levels ranged from 20 ng/mL to 160 ng/mL (mean: 75.8 ng/mL) and were significantly related to the improvement in [[negative symptoms]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124683\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_153       positive      2.6322          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Characteristic features of an [[inflammation]] induced by [[bevacizumab]] injection include an early onset with painless loss in VA mostly without conjunctival or ciliary injection.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124794\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_154       positive      2.4745          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/[[prednisone]]) chemotherapy is important to maximize response in patients with intermediate-or [[high-grade non-Hodgkin lymphoma]] but might be difficult in older patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124919\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_155       positive      2.5879          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Administration of full-dose R-CHOP ([[rituximab]]/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or [[high-grade non-Hodgkin lymphoma]] but might be difficult in older patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124759\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_156       positive      2.6209          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Administration of full-dose R-CHOP (rituximab/cyclophosphamide/[[doxorubicin]]/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or [[high-grade non-Hodgkin lymphoma]] but might be difficult in older patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124776\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_157       positive      2.3778          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Administration of full-dose R-CHOP (rituximab/[[cyclophosphamide]]/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or [[high-grade non-Hodgkin lymphoma]] but might be difficult in older patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124786\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_158       positive      2.6744          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/[[vincristine]]/prednisone) chemotherapy is important to maximize response in patients with intermediate-or [[high-grade non-Hodgkin lymphoma]] but might be difficult in older patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124858\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_159       positive      2.6092          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Compared with the general population, [[methotrexate]]-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and [[lung cancer]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124881\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_160       positive      2.3596          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Compared with the general population, [[methotrexate]]-treated RA patients have an increased incidence of [[melanoma]], non-Hodgkin's lymphoma, and lung cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707218352\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_161       positive      2.5421          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Compared with the general population, [[methotrexate]]-treated RA patients have an increased incidence of melanoma, [[non-Hodgkin's lymphoma]], and lung cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124795\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_163       positive      2.5873          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "There was an estimated 50% excess risk of malignancy among [[methotrexate]]-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in [[non-Hodgkin's lymphoma]] (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124835\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_165       positive      2.5078          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "There was an estimated 50% excess risk of malignancy among [[methotrexate]]-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in [[melanoma]] (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124852\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_166       positive      2.5598          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Incidence of melanoma and other malignancies among [[rheumatoid arthritis]] patients treated with [[methotrexate]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124894\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_167       positive      2.6836          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "To determine cancer risk in a cohort of 459 [[rheumatoid arthritis]] (RA) patients treated with [[methotrexate]] in community practice.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124828\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_169       positive      2.5666          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Incidence of melanoma and other [[malignancies]] among rheumatoid arthritis patients treated with [[methotrexate]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124721\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_170       positive      2.4892          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Incidence of [[melanoma]] and other malignancies among rheumatoid arthritis patients treated with [[methotrexate]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124803\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_172       positive      2.5666          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Absence of villin predisposes mice to [[dextran sodium sulfate]]-induced [[colitis]] by promoting apoptosis.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124727\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_176       positive      2.4221          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Finally, in non-small cell lung cancer (NSCLC) in patients' progressing on chemotherapy [[sutent]] was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for [[lung cancer]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124793\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_177       positive      2.5078          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "In several phase I/II/III studies, [[sutent]] was found to be effective as second and first line treatment in [[metastatic renal cell carcinoma]] (RCC).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124911\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_178       positive      2.5879          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Finally, in non-small cell lung cancer ([[NSCLC]]) in patients' progressing on chemotherapy [[sutent]] was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for lung cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124763\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_179       positive       2.397          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "[[Sutent]] was also effective as second line treatment in patients with gastrointestinal stromal tumors ([[GIST]]) with 8% response rate, 70% stable disease and a 20-month median survival.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124737\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_180       positive       2.397          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "In addition, a phase II study in multitreated women with [[breast cancer]], [[sutent]] demonstrated a moderate activity with 16% clinical benefit.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124739\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_181       positive      2.6039          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "[[Epoetin beta]] effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced [[anemia]] with a range of solid tumors and lymphoid malignancies.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124761\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_184       positive       2.397          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "During the induction phase, tacrolimus or cyclosporine, [[mycophenolate mofetil]], and methylprednisolone were used for [[immunosuppression]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124907\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_185       positive       2.609          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "During the induction phase, [[tacrolimus]] or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for [[immunosuppression]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124902\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_186       positive      2.5879          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and [[methylprednisolone]] were used for [[immunosuppression]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124758\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_187       positive      2.7424          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "During the induction phase, tacrolimus or [[cyclosporine]], mycophenolate mofetil, and methylprednisolone were used for [[immunosuppression]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124797\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_188       positive      2.5598          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "The most frequent and the most troublesome adverse effect of [[interferon]] plus ribavirin-based therapy is [[anaemia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124709\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_189       positive      2.4892          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "In multivariate analysis the risk of [[anaemia]] was significantly associated with [[zidovudine]] (OR, 3.27 95% CI, 1.64-6.54, P = 0.0008) and peg-IFN (OR, 2.35; 95% CI, 1.16-4.57, P = 0.0179).\n",
        "\n",
        "============================================================\n",
        "Unit id: 707284912\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_19       positive      2.4833          3              1      1\n",
        "\n",
        "The results from these studies, encompassing end points measuring lung function and symptoms, found that [[montelukast]] provided effective and beneficial [[asthma]] control to children aged 2 to 14 years with mild asthma.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124716\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_192       positive      2.4221          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "The most frequent and the most troublesome adverse effect of interferon plus [[ribavirin]]-based therapy is [[anaemia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124732\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_193       positive      2.4004          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "This study demonstrated that both low-dose topiramate and [[propranolol]] could significantly reduce [[migraine headache]] frequency, intensity, and duration.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707280277\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_194       positive      2.5879          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "This study demonstrated that both low-dose [[topiramate]] and propranolol could significantly reduce [[migraine headache]] frequency, intensity, and duration.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124825\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_197       positive      2.5666          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Long-term exposure to [[medium-dose glucocorticoid]] therapy associates with [[hypertension]] in patients with rheumatoid arthritis.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124883\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_20       positive      2.6092          3              1      1\n",
        "\n",
        "This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with [[montelukast]], a leukotriene receptor antagonist that is approved for the treatment of asthma and [[allergic rhinitis]] in children and adults.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124678\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_206       positive      4.1178          5              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "All three patients had recurrent admissions for stomal bleeding and [[stomal varices secondary to portal hypertension]] and were initially treated with local measures (pressure, [[silver nitrate]], and suture ligation).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124774\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_207       positive      2.4867          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "All three patients had recurrent admissions for [[stomal bleeding]] and stomal varices secondary to portal hypertension and were initially treated with local measures (pressure, [[silver nitrate]], and suture ligation).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124863\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_209       positive      2.5879          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did [[allopurinol]] (300 or 100 mg) or placebo in subjects with [[hyperuricemia]] and gout, including those with mild to moderately impaired renal function.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124811\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_21       positive      2.3788          3              1      1\n",
        "\n",
        "The combination of high-dose MTX with [[procarbazine]] and CCNU is feasible and effective and results in a low rate of [[leukoencephalopathy]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124748\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_210       positive      2.5845          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "A significantly (P < 0.05) higher percentage of subjects with [[impaired renal function]] treated with [[febuxostat]] 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of allopurinol (0 [0%] of 10).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124730\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_212       positive      2.4221          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "At all doses studied, [[febuxostat]] more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and [[gout]], including those with mild to moderately impaired renal function.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124789\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_214       positive      2.5598          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "At all doses studied, [[febuxostat]] more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with [[hyperuricemia]] and gout, including those with mild to moderately impaired renal function.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124815\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_216       positive      2.5078          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "The primary reasons for withdrawal were similar across groups except for [[gout flares]], which were more frequent with [[febuxostat]] than with allopurinol.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124906\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_217       positive      2.4833          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although diarrhea and [[dizziness]] were more frequent in the [[febuxostat]] 240 mg group.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124814\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_218       positive      2.5078          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although [[diarrhea]] and dizziness were more frequent in the [[febuxostat]] 240 mg group.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706694486\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_22       positive      2.4148          3              1      1\n",
        "\n",
        "The combination of [[high-dose MTX]] with procarbazine and CCNU is feasible and effective and results in a low rate of [[leukoencephalopathy]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124728\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_220       positive      2.4221          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "While the association between [[neural tube defects]] and [[antiepileptic drugs]] is well recognised, other congenital malformations are known to occur.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124871\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_224       positive        2.85          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "The patient was on corticosteroids and [[azathioprine]] for [[autoimmune hepatitis]] at the time of her presentation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124734\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_225       positive      2.5589          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "[[Pulmonary alveolar proteinosis]]: a rare pulmonary toxicity of [[sirolimus]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707276727\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_226       positive      2.4148          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "[[PAP]] is a very rare complication of [[SRL]] therapy with only a few cases described.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124837\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_23       positive      2.3778          3              1      1\n",
        "\n",
        "The combination of high-dose MTX with procarbazine and [[CCNU]] is feasible and effective and results in a low rate of [[leukoencephalopathy]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707283394\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_230       positive      2.4148          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "All patients converted to SRL because of [[GI side effects]] of [[MMF]] showed improvements, and none of those converted because of hyperglycemia experienced improvement.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124879\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_231       positive      2.4833          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of [[severe diarrhea]] due to [[MMF]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124779\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_236       positive      2.5598          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Our data showed that [[oxcarbazepine]] can be a good alternative to traditional antiepileptic agents in the prevention of [[perioperative seizures]] being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124895\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_240       positive       2.609          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Oral BDP prevents [[relapses of gastrointestinal GVHD]] following tapering of [[prednisone]]; survival is statistically significantly better among patients receiving BDP.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124840\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_241       positive      2.4848          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Oral BDP prevents [[relapses of gastrointestinal GVHD]] following tapering of prednisone; survival is statistically significantly better among patients receiving [[BDP]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124736\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_242       positive      2.4004          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Grade 3 or 4 leukopenia and [[edema]] and various grade 1 or 2 adverse events were more frequent in patients receiving eight [[TAC]] cycles than in those receiving six cycles.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124697\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_243       positive       2.397          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Grade 3 or 4 [[leukopenia]] and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight [[TAC]] cycles than in those receiving six cycles.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124874\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_25       positive      2.6092          3              1      1\n",
        "\n",
        "Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same [[pain]] relief as [[intravenous meperidine]] and diazepam.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124798\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_27       positive      2.3788          3              1      1\n",
        "\n",
        "Intra-articular injection of lidocaine before closed reduction of [[anterior shoulder dislocation]] produces the same pain relief as intravenous meperidine and [[diazepam]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124870\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_28       positive       2.609          3              1      1\n",
        "\n",
        "Intra-articular injection of lidocaine before closed reduction of [[anterior shoulder dislocation]] produces the same pain relief as [[intravenous meperidine]] and diazepam.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124698\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_30       positive      2.4686          3              1      1\n",
        "\n",
        "[[Intra-articular injection of lidocaine]] before closed reduction of anterior shoulder dislocation produces the same [[pain]] relief as intravenous meperidine and diazepam.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124910\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_32       positive      2.6836          3              1      1\n",
        "\n",
        "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of [[indomethacin-loaded nanocapsules]] or indomethacin ethyl ester-loaded nanocapsules, in [[glioma]] cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124735\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_34       positive      2.7424          3              1      1\n",
        "\n",
        "The main finding of the present study is that [[indomethacin-loaded nanocapsules]] formulation was more potent than a solution of indomethacin in decreasing the viability and cell proliferation of [[glioma]] lines.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124889\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_36       positive      2.6836          3              1      1\n",
        "\n",
        "In addition, when the [[glioma]] cells were exposed to 25 microM of indomethacin-loaded nanocapsules or [[indomethacin ethyl ester-loaded nanocapsules]], a necrotic cell death was observed.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124806\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_38       positive      2.4245          3              1      1"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "In addition, when the [[glioma]] cells were exposed to 25 microM of [[indomethacin-loaded nanocapsules]] or indomethacin ethyl ester-loaded nanocapsules, a necrotic cell death was observed.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124733\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_42       positive      2.4892          3              1      1\n",
        "\n",
        "Indomethacin and [[indomethacin ethyl ester]] associated together in the same nanocapsule formulation caused a synergic effect decreasing [[glioma]] cell proliferation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124884\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_43       positive      2.3596          3              1      1\n",
        "\n",
        "[[Indomethacin]] and indomethacin ethyl ester associated together in the same nanocapsule formulation caused a synergic effect decreasing [[glioma]] cell proliferation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124853\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_47       positive      2.3778          3              1      1\n",
        "\n",
        "We describe a patient with acute lymphocytic leukemia (ALL) who developed [[visceral varicella-zoster virus]] (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with [[intravenous acyclovir]] (ACV).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124807\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_48       positive      2.5078          3              1      1\n",
        "\n",
        "We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus ([[VZV) infection]] following cord blood stem cell transplantation (CBSCT) and was successfully treated with [[intravenous acyclovir]] (ACV).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124704\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "       pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_5       positive       2.397          3              1      1\n",
        "\n",
        "However, decreased tear production after [[botulinum toxin]] injection for crow's feet is a possible complication and patients should be advised of the small but definite risk of a temporary [[dry eye]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124707\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_50       positive      2.4004          3              1      1\n",
        "\n",
        "Although the role of [[clozapine]] is well established for [[treatment-resistant schizophrenia]], it is rarely used in pediatric populations, mainly due to its potentially serious adverse effects.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124893\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_51       positive      2.3596          3              1      1\n",
        "\n",
        "To summarize practical aspects of use of [[clozapine]] in treating children with [[schizophrenia]] and management of associated adverse effects.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124854\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_53       positive      2.5598          3              1      1"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "[[Keratoacanthoma]] occurring within the [[red dye of a tattoo]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707285195\n",
        "\n",
        "EU-ADR answer: speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_55    speculative      2.6836          3              1      1\n",
        "\n",
        "Information from the SITE Cohort Study should clarify whether use of these [[immunosuppressive drugs]] for ocular inflammation increases the risk of mortality and [[fatal cancer]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124696\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_56       positive      2.7424          3              1      1\n",
        "\n",
        "Calculated detectable differences for mortality/[[fatal malignancy]] with respect to the general population are 22%/49% for [[antimetabolites]], 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124682\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_59       positive       2.397          3              1      1\n",
        "\n",
        "Calculated detectable differences for mortality/[[fatal malignancy]] with respect to the general population are 22%/49% for antimetabolites, 28%/62% for [[T-cell inhibitors]], and 36%/81% for alkylating agents.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124908\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "       pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_6       positive        2.85          3              1      1\n",
        "\n",
        "[[Botulinum toxins]] are potent neurotoxins used in a variety of [[neurological disorders]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124899\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_63       positive      2.3596          3              1      1\n",
        "\n",
        "There were consistent significant [[miosis]] in the right eyes with instilled [[Garcinia kola nut extract]] compared to the left eyes at 15, 30 and 45 minutes (p=0.0000).\n",
        "\n",
        "============================================================\n",
        "Unit id: 707283605\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_69       positive       2.609          3              1      1\n",
        "\n",
        "[[5-aminosalicylic acid]] inhibits [[colitis-associated colorectal dysplasias]] in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124892\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "       pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_7       positive      2.6836          3              1      1\n",
        "\n",
        "We describe the case of a 10-year-old boy who developed systemic weakness following treatment of [[spasticity]] with [[botulinum toxin type B]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124802\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_70       positive      2.4245          3              1      1"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/[[dextran sulfate sodium]] (DSS)-induced [[colitis-associated neoplasia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124843\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_77       positive      2.3034          3              1      1\n",
        "\n",
        "Administration of 75 mg/kg [[5-ASA]] decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias ([[tumor]] burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124738\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_79       positive      2.7424          3              1      1\n",
        "\n",
        "Administration of 75 mg/kg [[5-ASA]] decreased both the mean multiplicity of [[flat dysplasias]] (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 707287494\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "       pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_8       positive      2.3596          3              1      1\n",
        "\n",
        "We describe the case of a 10-year-old boy who developed [[systemic weakness]] following treatment of spasticity with [[botulinum toxin type B]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124915\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_81       positive      2.6092          3              1      1\n",
        "\n",
        "An inverse trend was observed between dose and multiplicity of [[colonic dysplasias]] in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg [[5-ASA]] exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124822\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_82       positive      2.3788          3              1      1\n",
        "\n",
        "[[Spinal cord infarction]] secondary to [[cocaine]] use.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124849\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_83       positive      2.5983          3              1      1\n",
        "\n",
        "[[Cocaine]] abuse is associated with [[cerebrovascular events]]; spinal cord effects are rarely reported.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124731\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_84       positive       2.397          3              1      1\n",
        "\n",
        "Although uncommon, [[cocaine]] abuse can cause [[spinal cord infarction]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707004997\n",
        "\n",
        "EU-ADR answer: speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_85    speculative      2.5421          3              1      1"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "We report two rheumatoid arthritis patients developing [[sarcoidosis]] possibly induced by [[etanercept]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124861\n",
        "\n",
        "EU-ADR answer: speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_90    speculative      2.3596          3              1      1\n",
        "\n",
        "Furthermore, there may be a relationship between [[statin]] dose and [[cancer]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124891\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_93       positive       2.609          3              1      1\n",
        "\n",
        "[[BiRD]] is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed [[multiple myeloma]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707286886\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_96       positive      2.5126          3              1      1\n",
        "\n",
        "In this study, a 2-year-old girl with [[nephropathic cystinosis]] and severe gastrointestinal dysmotility was treated with intravenous ([[i.v.) administration of cysteamine hydrochloride]] (HCl).\n",
        "\n",
        "============================================================\n",
        "Unit id: 707283447\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_97       positive        2.85          3              1      1\n",
        "\n",
        "The most common adverse effects associated with the use of [[posaconazole]] include headache, fever, nausea, vomiting, and [[diarrhea]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124817\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_98       positive      2.4564          3              1      1\n",
        "\n",
        "[[Posaconazole]] is noninferior to fluconazole for treatment of [[oropharyngeal candidiasis]] (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124715\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_10          false      4.2055          5       0.845378      1\n",
        "1  drug_disease_10       negative      0.7692          1       0.154622      0\n",
        "\n",
        "ET-1 mRNA expression was significantly higher in patients with [[CsA]]-induced gingival overgrowth (P <0.001) than in patients with [[periodontitis]] and the controls.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124687\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_12       positive      4.2616          5       0.840668      1\n",
        "1  drug_disease_12    speculative      0.8077          1       0.159332      0\n",
        "\n",
        "These results suggest that CsA can modulate the expression of ET-1 in gingival fibroblasts and [[CsA]]-induced [[gingival overgrowth]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124770\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_149       positive      4.1183          5       0.834255   \n",
        "0  drug_disease_149          false      0.8182          1       0.165745   \n",
        "\n",
        "   match  \n",
        "1      1  \n",
        "0      0  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, [[cytarabine]] and prednisone.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124816\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_175       positive      3.3668          4       0.808006   \n",
        "0  drug_disease_175          false      0.8000          1       0.191994   \n",
        "\n",
        "   match  \n",
        "1      1  \n",
        "0      0  \n",
        "\n",
        "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting [[heparin]] therapy prior to the planned dental procedure, which can result in [[thromboembolism]] and increased morbidity and mortality.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124773\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_46       positive      2.5245          3       0.774909      1\n",
        "0  drug_disease_46          false      0.7333          1       0.225091      0\n",
        "\n",
        "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of [[visceral varicella-zoster infection]] ameliorated with [[intravenous acyclovir]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124780\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_78       positive      2.5245          3       0.774909      1\n",
        "0  drug_disease_78          false      0.7333          1       0.225091      0\n",
        "\n",
        "An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg [[5-ASA]] exhibiting 56% of the number of [[dysplasias]] of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124742\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_191       positive      2.5509          3        0.76832   \n",
        "1  drug_disease_191    speculative      0.7692          1        0.23168   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "1      0  \n",
        "\n",
        "The risk of [[anaemia]] was lower in patients with higher baseline haemoglobin levels (OR, 0.35 95% CI, 0.26-0.49, P < 0.0001) and in patients receiving [[protease inhibitor]]-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124844\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_204       positive      2.6696          3       0.766664   \n",
        "1  drug_disease_204    speculative      0.8125          1       0.233336   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "1      0  \n",
        "\n",
        "Compared with both diuretics and contemporary agents, [[amlodipine]] decreases [[cardiovascular events]] to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124713\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_35       positive      2.5455          3       0.764139      1\n",
        "1  drug_disease_35    speculative      0.7857          1       0.235861      0\n",
        "\n",
        "The main finding of the present study is that indomethacin-loaded nanocapsules formulation was more potent than a [[solution of indomethacin]] in decreasing the viability and cell proliferation of [[glioma]] lines.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124775\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_111       positive      2.5901          3       0.764019   \n",
        "0  drug_disease_111          false      0.8000          1       0.235981   \n",
        "\n",
        "   match  \n",
        "1      1  \n",
        "0      0  \n",
        "\n",
        "[[Posaconazole]], in doses of 200 mg 3 times daily, reduced breakthrough [[invasive fungal infections]] (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124804"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_24       positive      2.5901          3       0.764019      1\n",
        "0  drug_disease_24          false      0.8000          1       0.235981      0\n",
        "\n",
        "[[Intra-articular injection of lidocaine]] before closed reduction of [[anterior shoulder dislocation]] produces the same pain relief as intravenous meperidine and diazepam.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124916\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_195       positive      2.5483          3       0.759327   \n",
        "0  drug_disease_195          false      0.8077          1       0.240673   \n",
        "\n",
        "   match  \n",
        "1      1  \n",
        "0      0  \n",
        "\n",
        "Results - The [[topiramate]] group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, [[headache]] intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124757\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_164       positive      2.5971          3       0.757084   \n",
        "0  drug_disease_164          false      0.8333          1       0.242916   \n",
        "\n",
        "   match  \n",
        "1      1  \n",
        "0      0  \n",
        "\n",
        "There was an estimated 50% excess risk of malignancy among [[methotrexate]]-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in [[lung cancer]] (SIR 2.9, 95% CI 1.6-4.8).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124726\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_29       positive      2.5971          3       0.757084      1\n",
        "0  drug_disease_29          false      0.8333          1       0.242916      0\n",
        "\n",
        "Mean [[pain]] (mm) recorded before injection, before reduction, and after reduction in the [[intra-articular lidocaine]] group was 84.3 (95% confidence interval (CI) 79.8 to 88.8), 52.6 (95% CI 45.2 to 60.1), and 27.3 (95% CI 19.9 to 34.7), respectively.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124772\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_128       positive      2.4854          3        0.75473   \n",
        "1  drug_disease_128    speculative      0.8077          1        0.24527   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "1      0  \n",
        "\n",
        "Our findings support that ecstasy use, or [[ecstasy/cannabis]] synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for [[long-term cognitive impairment]] owing to ecstasy consumption in the context of polydrug use.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707780960\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_234       positive      2.8611          3       0.754032   \n",
        "0  drug_disease_234       negative      0.9333          1       0.245968   \n",
        "\n",
        "   match  \n",
        "1      1  \n",
        "0      0  \n",
        "\n",
        "Moreover, [[oxcarbazepine]] can be a valid choice when long-term therapy is required because of the low interaction with other drugs and the low [[hematological side effects]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124831\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_211       positive      2.4999          3       0.753413   \n",
        "1  drug_disease_211    speculative      0.8182          1       0.246587   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "1      0  \n",
        "\n",
        "The primary reasons for withdrawal were similar across groups except for [[gout flares]], which were more frequent with febuxostat than with [[allopurinol]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124796\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_201       positive      2.4696          3       0.749932   \n",
        "1  drug_disease_201    speculative      0.8235          1       0.250068   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "1      0  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Collectively, the cardiovascular benefit, metabolic neutrality and homogeneous blood pressure response illuminated in recent studies, and reviewed here, represent a reaffirmation of the benefit of [[long-acting dihydropyridine calcium channel antagonists]] and should serve to help reinforce the critical importance of these agents in the therapeutic armamentarium against [[cardiovascular disease]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124694\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_127       positive      5.1121          6       0.745802   \n",
        "1  drug_disease_127    speculative      1.7424          2       0.254198   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "1      0  \n",
        "\n",
        "[[Oritavancin]]: a new promising agent in the treatment of [[infections due to Gram-positive pathogens]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706985414\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_105       positive      2.4421          3       0.745588   \n",
        "0  drug_disease_105       negative      0.8333          1       0.254412   \n",
        "\n",
        "   match  \n",
        "1      1  \n",
        "0      0  \n",
        "\n",
        "The most common adverse effects associated with the use of [[posaconazole]] include [[headache]], fever, nausea, vomiting, and diarrhea.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706989513\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_117       positive      2.4451          3       0.740446   \n",
        "1  drug_disease_117    speculative      0.8571          1       0.259554   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "1      0  \n",
        "\n",
        "It is well known that [[tobacco smoke]] exposure is related to the risk of developing [[cardiovascular diseases]] and events.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124747\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_52       positive      2.5564          3       0.737671      1\n",
        "1  drug_disease_52    speculative      0.9091          1       0.262329      0\n",
        "\n",
        "Despite a higher incidence of adverse effects in children, [[clozapine]] appears to be a uniquely beneficial second-line agent for treating children with [[refractory schizophrenia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124848\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "2  drug_disease_103       positive      4.3053          5       0.731597   \n",
        "0  drug_disease_103          false      0.8462          1       0.143794   \n",
        "1  drug_disease_103       negative      0.7333          1       0.124609   \n",
        "\n",
        "   match  \n",
        "2      1  \n",
        "0      0  \n",
        "1      0  \n",
        "\n",
        "Similarly, the same regimen of [[posaconazole]] reduced invasive fungal infections (95% CI -9.7 to -2.5) and [[aspergillosis]] (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124768\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_15       positive      4.0652          5       0.719695      1\n",
        "1  drug_disease_15    speculative      1.5833          2       0.280305      0\n",
        "\n",
        "The evidence suggests that [[montelukast]] is an effective monotherapy controller in children with [[mild asthma]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124846\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_26       positive      1.7594          2       0.707524      1\n",
        "0  drug_disease_26          false      0.7273          1       0.292476      0\n",
        "\n",
        "Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same [[pain]] relief as intravenous meperidine and [[diazepam]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124710"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_196       positive      1.8517          2       0.706513   \n",
        "0  drug_disease_196       negative      0.7692          1       0.293487   \n",
        "\n",
        "   match  \n",
        "1      1  \n",
        "0      0  \n",
        "\n",
        "Results - The [[topiramate]] group showed a reduction in the mean (+/-SD) of monthly [[migraine]] frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).\n",
        "\n",
        "============================================================\n",
        "Unit id: 707278758\n",
        "\n",
        "EU-ADR answer: speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_74    speculative      1.8398          2       0.705174      1\n",
        "0  drug_disease_74       positive      0.7692          1       0.294826      0\n",
        "\n",
        "The impact of the antiinflammatory agent 5-aminosalicylic acid ([[5-ASA]]) on the risk for [[colitis-associated colorectal cancer]] remains controversial.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124877\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_139       positive      1.7500          2       0.704707   \n",
        "1  drug_disease_139    speculative      0.7333          1       0.295293   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "1      0  \n",
        "\n",
        "For exposure levels within standard recommended guidelines, [[radioisotopes]] are far more likely to play a role in the occurrence of [[spontaneous abortions]] than X-rays.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707283108\n",
        "\n",
        "EU-ADR answer: speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_71    speculative      1.7333          2       0.697983      1\n",
        "0  drug_disease_71       positive      0.7500          1       0.302017      0\n",
        "\n",
        "These data suggest that [[low-dose 5-ASA]] may be efficacious in preventing [[colitis-associated dysplasias]] and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124756\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_11       positive      1.9091          2       0.696142      1\n",
        "0  drug_disease_11       negative      0.8333          1       0.303858      0\n",
        "\n",
        "ET-1 mRNA expression was significantly higher in patients with [[CsA]]-induced [[gingival overgrowth]] (P <0.001) than in patients with periodontitis and the controls.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124723\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "2  drug_disease_215       positive      5.2462          6       0.690190   \n",
        "1  drug_disease_215       negative      1.5549          2       0.204562   \n",
        "0  drug_disease_215          false      0.8000          1       0.105248   \n",
        "\n",
        "   match  \n",
        "2      1  \n",
        "1      0  \n",
        "0      0  \n",
        "\n",
        "A significantly (P < 0.05) higher percentage of subjects with [[impaired renal function]] treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of [[allopurinol]] (0 [0%] of 10).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124912\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_168       positive      1.6648          2       0.689415   \n",
        "1  drug_disease_168    speculative      0.7500          1       0.310585   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "1      0  \n",
        "\n",
        "To determine [[cancer]] risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with [[methotrexate]] in community practice.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124856\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_213       positive      1.6648          2       0.689415   \n",
        "1  drug_disease_213    speculative      0.7500          1       0.310585   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "1      0  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "At all doses studied, [[febuxostat]] more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately [[impaired renal function]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124686\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "2  drug_disease_108       positive      5.3364          6       0.682867   \n",
        "0  drug_disease_108          false      1.7091          2       0.218703   \n",
        "1  drug_disease_108       negative      0.7692          1       0.098430   \n",
        "\n",
        "   match  \n",
        "2      1  \n",
        "0      0  \n",
        "1      0  \n",
        "\n",
        "Similarly, the same regimen of posaconazole reduced [[invasive fungal infections]] (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with [[fluconazole]] and itraconazole in neutropenic patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124850\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_95       positive      4.9582          6       0.668672      1\n",
        "2  drug_disease_95    speculative      1.6568          2       0.223439      0\n",
        "0  drug_disease_95          false      0.8000          1       0.107889      0\n",
        "\n",
        "A multipronged approach to limit [[endophthalmitis]] risk is also needed, with [[antibiotics]] as only part of the strategy.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124917\n",
        "\n",
        "EU-ADR answer: speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_115    speculative      4.8437          6       0.655733   \n",
        "0  drug_disease_115       positive      2.5430          3       0.344267   \n",
        "\n",
        "   match  \n",
        "1      1  \n",
        "0      0  \n",
        "\n",
        "While some beneficial neuromotor effects of succimer therapy were observed in the present study there remains several unanswered questions such as how long these effects will persist and how [[succimer]] therapy modifies lead-associated [[cerebellar deficits]] manifesting as perturbations in vestibular and/or proprioception systems for postural balance and functional locomotion.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124681\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "2  drug_disease_99       positive      4.4928          5       0.589367      1\n",
        "0  drug_disease_99          false      1.6278          2       0.213535      0\n",
        "1  drug_disease_99       negative      1.5025          2       0.197098      0\n",
        "\n",
        "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and [[aspergillosis]] (CI not reported, p < 0.001) when compared with fluconazole and [[itraconazole]] in neutropenic patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124805\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "2  drug_disease_100       positive      4.3753          5       0.574858   \n",
        "0  drug_disease_100          false      1.7333          2       0.227733   \n",
        "1  drug_disease_100       negative      1.5025          2       0.197409   \n",
        "\n",
        "   match  \n",
        "2      1  \n",
        "0      0  \n",
        "1      0  \n",
        "\n",
        "Similarly, the same regimen of posaconazole reduced [[invasive fungal infections]] (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and [[itraconazole]] in neutropenic patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124679\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_114       positive      4.6257          5       0.569576   \n",
        "0  drug_disease_114          false      3.4956          4       0.430424   \n",
        "\n",
        "   match  \n",
        "1      1  \n",
        "0      0  \n",
        "\n",
        "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and [[aspergillosis]] incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving [[fluconazole]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124904\n",
        "\n",
        "EU-ADR answer: speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_72    speculative      4.3107          5       0.567773      1\n",
        "0  drug_disease_72       positive      3.2816          4       0.432227      0\n",
        "\n",
        "These data suggest that [[low-dose 5-ASA]] may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of [[colonic neoplasms]] in patients with ulcerative colitis.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124684"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "2  drug_disease_65       positive      4.2677          5       0.556589      1\n",
        "1  drug_disease_65       negative      2.5999          3       0.339076      0\n",
        "0  drug_disease_65          false      0.8000          1       0.104335      0\n",
        "\n",
        "There is evidence in the literature that [[inhaled corticosteroids]] (ICSs) are safe for pregnant women with [[asthma]] and their infants.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124782\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "2  drug_disease_64       positive      4.1098          5       0.556567      1\n",
        "0  drug_disease_64          false      2.4619          3       0.333401      0\n",
        "1  drug_disease_64       negative      0.8125          1       0.110032      0\n",
        "\n",
        "There is evidence in the literature that inhaled corticosteroids ([[ICSs]]) are safe for pregnant women with [[asthma]] and their infants.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124767\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_221       positive      4.1666          5       0.543992   \n",
        "2  drug_disease_221    speculative      1.8745          2       0.244735   \n",
        "0  drug_disease_221          false      1.6182          2       0.211273   \n",
        "\n",
        "   match  \n",
        "1      1  \n",
        "2      0  \n",
        "0      0  \n",
        "\n",
        "While the association between neural tube defects and [[antiepileptic drugs]] is well recognised, other [[congenital malformations]] are known to occur.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124762\n",
        "\n",
        "EU-ADR answer: speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "3  drug_disease_73    speculative      4.1809          5       0.540342      1\n",
        "2  drug_disease_73       positive      1.8643          2       0.240943      0\n",
        "0  drug_disease_73          false      0.9231          1       0.119302      0\n",
        "1  drug_disease_73       negative      0.7692          1       0.099412      0\n",
        "\n",
        "These data suggest that [[low-dose 5-ASA]] may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with [[ulcerative colitis]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124706\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_33       positive      3.9401          5       0.536703      1\n",
        "1  drug_disease_33    speculative      3.4012          4       0.463297      0\n",
        "\n",
        "Selective cytotoxicity of [[indomethacin]] and indomethacin ethyl ester-loaded nanocapsules against [[glioma]] cell lines: an in vitro study.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124841\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_62       positive      3.4887          4       0.469846      1\n",
        "0  drug_disease_62          false      3.1240          4       0.420729      0\n",
        "2  drug_disease_62    speculative      0.8125          1       0.109425      0\n",
        "\n",
        "Calculated detectable differences for mortality/[[fatal malignancy]] with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for [[alkylating agents]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124744\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "2  drug_disease_148       positive      3.4811          4       0.449900   \n",
        "0  drug_disease_148          false      1.7564          2       0.226998   \n",
        "3  drug_disease_148    speculative      1.7308          2       0.223690   \n",
        "1  drug_disease_148       negative      0.7692          1       0.099412   \n",
        "\n",
        "   match  \n",
        "2      1  \n",
        "0      0  \n",
        "3      0  \n",
        "1      0  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, [[vincristine]] and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124771"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "2  drug_disease_39       positive      3.3362          4       0.447092      1\n",
        "1  drug_disease_39       negative      2.5743          3       0.344988      0\n",
        "3  drug_disease_39    speculative      0.8182          1       0.109649      0\n",
        "0  drug_disease_39          false      0.7333          1       0.098271      0\n",
        "\n",
        "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or [[indomethacin ethyl ester-loaded nanocapsules]], in [[glioma]] cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124855\n",
        "\n",
        "EU-ADR answer: positive\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "2  drug_disease_208       positive      3.2009          4       0.436554   \n",
        "3  drug_disease_208    speculative      1.7647          2       0.240678   \n",
        "0  drug_disease_208          false      1.6333          2       0.222757   \n",
        "1  drug_disease_208       negative      0.7333          1       0.100011   \n",
        "\n",
        "   match  \n",
        "2      1  \n",
        "3      0  \n",
        "0      0  \n",
        "1      0  \n",
        "\n",
        "At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did [[allopurinol]] (300 or 100 mg) or placebo in subjects with hyperuricemia and [[gout]], including those with mild to moderately impaired renal function.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124783\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_37          false      3.1163          4       0.422023      1\n",
        "1  drug_disease_37       positive      2.5158          3       0.340700      0\n",
        "2  drug_disease_37    speculative      1.7521          2       0.237277      0\n",
        "\n",
        "Selective cytotoxicity of indomethacin and [[indomethacin ethyl ester-loaded nanocapsules]] against [[glioma]] cell lines: an in vitro study.\n",
        "\n",
        "============================================================\n"
       ]
      }
     ],
     "prompt_number": 23
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "def graph_confidence(work_units):\n",
      "    conf = []\n",
      "    \n",
      "    for rel_id in work_units:\n",
      "        group = results.query(\"pub_rel_id == '{0}'\".format(rel_id))\n",
      "        \n",
      "        conf.append(group.iloc[0][\"percent_agree\"])\n",
      "        \n",
      "    graph = pd.Series(sorted(conf, reverse = True)).plot()\n",
      "    \n",
      "    graph.set_ylim((0, 1.1))"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 28
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "graph_confidence(matches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "metadata": {},
       "output_type": "display_data",
       "png": "iVBORw0KGgoAAAANSUhEUgAAAXAAAAD7CAYAAABzGc+QAAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\nAAAASUVORK5CYII=\n",
       "text": [
        "<matplotlib.figure.Figure at 0x7fb5af3ea490>"
       ]
      }
     ],
     "prompt_number": 25
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "graph_confidence(mismatches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "metadata": {},
       "output_type": "display_data",
       "png": "iVBORw0KGgoAAAANSUhEUgAAAW8AAAD7CAYAAAClvBX1AAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\n",
       "text": [
        "<matplotlib.figure.Figure at 0x7fb5af3cd450>"
       ]
      }
     ],
     "prompt_number": 26
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "graph_confidence(matches + mismatches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "metadata": {},
       "output_type": "display_data",
       "png": "iVBORw0KGgoAAAANSUhEUgAAAW8AAAD7CAYAAAClvBX1AAAABHNCSVQICAgIfAhkiAAAAAlwSFlz\nAAALEgAACxIB0t1+/AAAF35JREFUeJzt3X20XHV97/H315NAQxJWIlgieeAYjeHhwj2oQATRU3Rp\nAtV4WwpEUQ4CxqXRpixrBFqh60aE622JFBaCoMcrlPhQ2+KqFBHutJRYEJpAJCSAMZY8YeWaVhBK\nIL/7x57knMw+TzmZOXvPzPu11izOntnM+flh/Gbymb33REoJSVJzeVXRC5Ak7TuHtyQ1IYe3JDUh\nh7ckNSGHtyQ1IYe3JDWhcWP1iyLCYxIlaRRSSlF735i+804peet3u/zyywtfQ9luZmImZrL3bTDW\nJgXatGlT0UsoHTPJM5M8M3F4S1JTcngXqKenp+gllI6Z5JlJnplADNWp1PUXRaSx+l2S1CoiglT0\nB5baW6VSKXoJpWMmeWaSZyYOb0lqStYmklRi1iaS1EIc3gWyt8szkzwzyTMTh7ckNSU7b0kqMTtv\nSWohDu8C2dvlmUmemeSZyQiGd0R8NSKeiYi1Q+xzbUQ8GRGPRMTx9V2iJKnWsJ13RJwKPAf8n5TS\nsQM8fjqwJKV0ekScBHwppTRvgP3svCVpH426804p3Qf8aohd3gd8vbrvA8CUiDhstAuVJA2vHp33\ndODpftubgRl1eN6WZ2+XZyZ5ZpJnJvX7GrTat/QD9iMXXlin39Yitm2DW28tehXlYiZ9TjkFzj+/\n6FWorOoxvLcAM/ttz6jel7NuXQ+HHtoJwIQJU5g1q4u5c7sB2LChAtBW21Onwty5lGY9ZdieN69c\n6ylq+957K/zFX8D553fT3d29551md3f2eLtv776vLOup53alUqG3txeAzs5OBjOik3QiohP43gg+\nsJwHrPADS2n/rF4NH/lI9k+1t1F/YBkRtwOrgLkR8XREfCQiFkfEYoCU0veBjRHxFHAj8PE6r71l\n2dvlmUlm4kR4/vnsZzPJM5MR1CYppUUj2GdJfZYjCbLh/dxzRa9CZea1TaQS2rEDjjgC/uM/il6J\niua1TaQmsrs28f2OBuPwLpC9XZ6ZZMaPh44OeOklMxmImTi8pdKy99ZQ7Lylkpo5E+6/H2bNKnol\nKpKdt9Rk+h8uKNVyeBfI3i7PTPpMmpQNbzPJMxOHt1Radt4aip23VFKnnw6f+ASccUbRK1GR7Lyl\nJmPnraE4vAtkb5dnJn3svAdnJg5vqbTsvDUUO2+ppJYtg6lT4bOfLXolKpKdt9Rk7Lw1FId3gezt\n8sykz+7hbSZ5ZuLwlkpr0iQ7bw3OzlsqqVtvhTvvhNtuK3olKpKdt9Rk7Lw1FId3gezt8sykj533\n4MzE4S2Vlp23hmLnLZXUI4/Ahz4Ejz5a9EpUJDtvqcnYeWsoDu8C2dvlmUkfO+/BmYnDWyotO28N\nxc5bKqlXXsm+Rf6VVyByjafahZ231GQ6OuDAA+GFF4peicrI4V0ge7s8M9nbxIlw112VopdROr5O\nHN5Sqb31rbB8OWzdWvRKVDZ23lKJvfxyNrx7e+Huu2HOnKJXpLFm5y01oXHj4Ior4LLL4OST4Ytf\nzAa65PAukL1dnpnkVSoVLroI/vEfYeXK7GqD7c7XicNbahpHH519Ndrttxe9EpXBsJ13RMwHVgAd\nwM0ppatrHj8UuBWYBowD/ndKqXeA57HzlvbTb34D06fD+vVw2GFFr0ZjYVSdd0R0ANcB84GjgUUR\ncVTNbkuA1SmlLqAb+POIGFeXVUvay0EHwXvfm32AqfY2XG1yIvBUSmlTSmknsBJYWLPPNuDg6s8H\nA8+mlPxIZQTs7fLMJK82k4svhi9/GRYuhF27illT0XydDD+8pwNP99veXL2vv68Ax0TEVuAR4A/r\ntzxJtbq6YMMG+MlP4LHHil6NijJcvTGSkvpSYE1KqTsiXg/cHRH/PaX069ode3p66OzsBGDKlCl0\ndXXR3d0N9P1J2m7bu5VlPW6Xb7u7uzv3+KpVFebOhfvu6+bYY8u13rHY3n1fWdZTz+1KpUJvtRfb\nPS8HMuQHlhExD7gipTS/un0JsKv/h5YR8X3g8yml+6vb9wDLUkoP1TyXH1hKddTbC3fd5dEnrW60\nJ+k8BMyJiM6IOAA4G7ijZp/1wLuqv+QwYC6wcf+X3Pp2/2mrPmaSN1gmp54K//RP0I7viXydDDO8\nqx88LgHuAtYB30wpPR4RiyNicXW3K4G3RMQjwA+Bz6SU/l8jFy0JZs/OBvfPflb0SlQEr20iNbFz\nz4WXXoJrroHDD/e6363Ia5tILej662HWrOzsy4kTYepUOOQQOPJIuPPOolenRvKdd4H6f1qujJnk\njTST556DnTuzY78ffhg+9jE4+GA44YTsSx3e/GZYsACmTWv8mhutnV4ng73z9kxIqUVMmtT387vf\nDU88AQ88kB0P/sIL2ZEpF18MRx0FkyfDb/1WNtQPPLDv5yOPhAsvzLZVbr7zltrI88/Dj3+cDfP/\n+q/s9uKLfT/fcw/86EdZFXPccfCud8GECdnlaH/7t4tefXsa7J23w1vSXn76U/jlL2HVKrj//uxi\nWKtWZUe3vPa12QejCxfCGWf4AelYcHiXUDv1diNlJnllyOT55+Hxx2HbNvi3f4OvfAW2b88+IJ08\nOfvnEUfA7/4uvOlN2RUPx41r3HAvQyZjxc5b0qhNnAhveUvf9sc/Dps3w69/nd1+9atsuK9YkV2u\n9he/yIb6TTfBH/xBcetuZb7zltQQDz+cDe43vhE+8xk47bSiV9ScrE0kjbkXXoBvfxsuvTQ7imXh\nwuyIlgkTil5Z8/AknRLy+gx5ZpLXzJlMmAAf/jA8+GB2yOKHPwxz58LNN8PPfz76523mTOrF4S2p\n4Q4/HL7zHVi7Fv7qr+Dv/z47eeiYY+BLX4KX/fqWfWZtIqkQu3ZlJxH96Z/C1q3ZGaC7D0WcORPe\n9z4YP77oVRbPzltSKaUE992XXR1x27bs9vDD2an+f/Zn2fHls2a171mfDu8SaqdjVUfKTPLaMZOU\nsotuffe7WTe+ZUv2Tvy887LDFrdurXDWWd2Ma4ODnT3OW1LTiIAlS7IbZCcJXX89XHttdgTLhg1w\n/vnZO/LXvS77YHTy5Oz7PZcupT2Guu+8JTWjF1+ETZuyuuWll2DHDrjtNujogAsugNe8BubNyy64\n1cysTSS1vN09+fr12Wn8P/0p3HprdincZuVx3iXksap5ZpJnJnmDZTJ+PCxfnh2W+OCD8L3vZfXK\nwoWweDF86lPZaf2twOEtqWWdfDL8679mJwcdf3w23N/+9qxuaXbWJpLaylVXwb33wg9+UPRKRsbO\nW5LIPtycOzfrwk85pejVDM/Ou4TsMvPMJM9M8vYnkwMOgMsuy/rvG27ILmnbjNrgaEhJ2tt552WH\nFn7zm9l3fV5zTdEr2nfWJpLa1vbt2cWxVq/OTvgpI2sTSaoxbVp2COHy5UWvZN85vAtkl5lnJnlm\nklfPTC6+OPvCiO3b6/aUY8LhLamtHXoonHNOdu2UZmLnLantPfFEdtjgli3Z0ShlYuctSYN44xvh\n4IOb68xLh3eB7DLzzCTPTPIakcns2dkVCpuFw1uSyK4LvnFj0asYOTtvSSK75smzz8IXv1j0SvY2\n6s47IuZHxPqIeDIilg2yT3dErI6In0REpQ7rlaQxNXt2c73zHnJ4R0QHcB0wHzgaWBQRR9XsMwW4\nHnhvSum/AWc2aK0txy4zz0zyzCSvUZ13ywxv4ETgqZTSppTSTmAlsLBmnw8Af51S2gyQUvpl/Zcp\nSY21e3g3S7s7ZOcdEWcC70kpXVTdPhc4KaX0yX77XAOMB44BJgNfSil9Y4DnsvOWVFopwdSp2Ven\nHXJI0avpM9pvjx/JtB0PvAl4J3AQ8KOI+JeU0pO1O/b09NDZ2QnAlClT6Orqoru7G+j7a5Dbbrvt\ndlHbs2d3s3EjrF1b3HoqlQq9vb0Ae+blQIZ75z0PuCKlNL+6fQmwK6V0db99lgETUkpXVLdvBv4h\npfSdmufynXeNSqWy5z+eMmaSZyZ5jcrkzDPhrLOyW1mM9miTh4A5EdEZEQcAZwN31Ozzd8DbIqIj\nIg4CTgLW1WPRkjSWTjgh+9LiZjDscd4RsQBYAXQAt6SUvhARiwFSSjdW9/k0cD6wC/hKSunaAZ7H\nd96SSu0//xNe/3q47z448siiV5PxOywlaQSuvBLuvBMuuADOPhsmTCh2PV6YqoR2f0ihPmaSZyZ5\njcxk6VJYuBBWroSTT4Yf/xheeaVhv27UHN6S1M9BB8GnP529+77wQvjQh2DSJHjNa+D008vTiVub\nSNIwfvObrA+vVGDZsuyr05Ytg46Oxv9uO29JqoOtW+EDH4Cf/zz7Aodx42Dy5Ox64MccA7//+3Dg\ngfX7fXbeJWSXmWcmeWaSV2Qmhx+evQP/1rfgPe+Bd7wD5szJPtj82teyL3bYsqXx6xjuDEtJ0gBO\nOCG79fcnfwKf/zwsWgT33pu9K28UaxNJqqNdu+D974dt2+Dqq+G00/bv+ey8JWmM7NoF3/42XHYZ\nvOENcPPNMGPG6J7LzruE7DLzzCTPTPLKnsmrXpWd4LNuHZx6Kpx0Ejz6aH1/h523JDXIAQdk776f\new5uvx2OO65+z21tIkkN9vWvww9/CN/IfdPB8KxNJKkgM2bA00/X9zkd3gUqe29XBDPJM5O8Zstk\n5kzYvLm+z+nwlqQGmz49G971bI7tvCVpDLz61bBhQ3aBq31h5y1JBap3deLwLlCz9XZjwUzyzCSv\nGTOZMcPhLUlNp95HnNh5S9IYWL48uy74lVfu279n5y1JBbI2aSHN2Ns1mpnkmUleM2ZS79rE4S1J\nY2DuXFizBm66qT7He9t5S9IYWbsWzjkH/viPoadnZP+O1/OWpBL453+Gc8/NTtgZyXdd+oFlCTVj\nb9doZpJnJnnNnMnb3pZ9UfGll8KOHaN/Hoe3JI2xv/zL7MiTI46AM86Az30u+0LjF18c+XNYm0hS\nQXbsgLvvhsceg1Wr4KGH4Nhj4aMfhQ9+MNvHzluSSm77dli9Gi66KPsW+vPOs/MupWbu7RrFTPLM\nJK9VM5k2DRYsgHvugT/6I3jmmcH3dXhLUsnMnQuLFsG11w6+j7WJJJXQxo1w4onw7LOjrE0iYn5E\nrI+IJyNi2RD7nRARL0fE7+3voiWp3c2eDR/72OCPDzm8I6IDuA6YDxwNLIqIowbZ72rgH4DcnxAa\nWKv2dvvDTPLMJK9dMlm+fPDHhnvnfSLwVEppU0ppJ7ASWDjAfp8EvgP8+yjXKEnaB0N23hFxJvCe\nlNJF1e1zgZNSSp/st8904FbgNOCrwPdSSt8d4LnsvCVpH432UMGRTNsVwGerkzmwNpGkhhs3zONb\ngJn9tmcCtZcTfzOwMiIADgUWRMTOlNIdtU/W09NDZ2cnAFOmTKGrq4vu7m6gr8Nqp+01a9awdOnS\n0qynDNu77yvLesqwXZtN0espw/aKFStadn5UKhV6e3sB9szLgQxXm4wDNgDvBLYCDwKLUkqPD7L/\n17A2GbFKpbLnP54yZpJnJnntlMmoT4+PiAVk1UgHcEtK6QsRsRggpXRjzb4Ob0mqI69tIklNyGub\nlFD/LlMZM8kzkzwzcXhLUlOyNpGkErM2kaQW4vAukL1dnpnkmUmemTi8Jakp2XlLUonZeUtSC3F4\nF8jeLs9M8swkz0wc3pLUlOy8JanE7LwlqYU4vAtkb5dnJnlmkmcmDm9Jakp23pJUYnbektRCHN4F\nsrfLM5M8M8kzE4e3JDUlO29JKjE7b0lqIQ7vAtnb5ZlJnpnkmYnDW5Kakp23JJWYnbcktRCHd4Hs\n7fLMJM9M8szE4S1JTcnOW5JKzM5bklqIw7tA9nZ5ZpJnJnlm4vCWpKZk5y1JJWbnLUktZETDOyLm\nR8T6iHgyIpYN8PgHI+KRiHg0Iu6PiOPqv9TWY2+XZyZ5ZpJnJiMY3hHRAVwHzAeOBhZFxFE1u20E\n3p5SOg74n8BN9V6oJKnPsJ13RLwVuDylNL+6/VmAlNJVg+w/FVibUppRc7+dtyTto/3pvKcDT/fb\n3ly9bzAXAN/ft+VJkvbFuBHsM+K3yxHxO8BHgFMGerynp4fOzk4ApkyZQldXF93d3UBfh9VO22vW\nrGHp0qWlWU8ZtnffV5b1lGG7Npui11OG7RUrVrTs/KhUKvT29gLsmZcDGUltMg+4ol9tcgmwK6V0\ndc1+xwHfBeanlJ4a4HmsTWpUKpU9//GUMZM8M8lrp0wGq01GMrzHARuAdwJbgQeBRSmlx/vtMwu4\nFzg3pfQvgzyPw1uS9tFgw3vY2iSl9HJELAHuAjqAW1JKj0fE4urjNwKfA6YCN0QEwM6U0on1/B8g\nSeozouO8U0p3ppTmppTekFL6QvW+G6uDm5TShSmlQ1JKx1dvDu4R6N9lKmMmeWaSZyaeYSlJTclr\nm0hSiXltE0lqIQ7vAtnb5ZlJnpnkmYnDW5Kakp23JJWYnbcktRCHd4Hs7fLMJM9M8szE4S1JTcnO\nW5JKzM5bklqIw7tA9nZ5ZpJnJnlm4vCWpKZk5y1JJWbnLUktxOFdIHu7PDPJM5M8M3F4S1JTsvOW\npBKz85akFuLwLpC9XZ6Z5JlJnpk4vCWpKdl5S1KJ2XlLUgtxeBfI3i7PTPLMJM9MHN6S1JTsvCWp\nxOy8JamFOLwLZG+XZyZ5ZpJnJg5vSWpKdt6SVGJ23pLUQoYd3hExPyLWR8STEbFskH2urT7+SEQc\nX/9ltiZ7uzwzyTOTPDMZZnhHRAdwHTAfOBpYFBFH1exzOvCGlNIc4KPADQ1aa8tZs2ZN0UsoHTPJ\nM5M8Mxn+nfeJwFMppU0ppZ3ASmBhzT7vA74OkFJ6AJgSEYfVfaUtaMeOHUUvoXTMJM9M8sxk+OE9\nHXi63/bm6n3D7TNj/5cmSRrMcMN7pIeH1H4S6mElI7Bp06ail1A6ZpJnJnlmMsyhghExD7gipTS/\nun0JsCuldHW/fb4MVFJKK6vb64F3pJSeqXkuB7okjcJAhwqOG+bfeQiYExGdwFbgbGBRzT53AEuA\nldVhv6N2cA/2yyVJozPk8E4pvRwRS4C7gA7glpTS4xGxuPr4jSml70fE6RHxFPA8cH7DVy1JbW7M\nzrCUJNVPw8+wHMlJPu0gIjZFxKMRsToiHqze9+qIuDsinoiIH0TElKLX2UgR8dWIeCYi1va7b9AM\nIuKS6utmfUS8u5hVN9YgmVwREZurr5XVEbGg32PtkMnMiPi/EfFYRPwkIj5Vvb+tXys5KaWG3ciq\nlqeATmA8sAY4qpG/s6w34GfAq2vu+1/AZ6o/LwOuKnqdDc7gVOB4YO1wGZCdFLam+rrprL6OXlX0\n/4YxyuRy4OIB9m2XTKYBXdWfJwEbgKPa/bVSe2v0O++RnOTTTmo/tN1zglP1n+8f2+WMrZTSfcCv\nau4eLIOFwO0ppZ0ppU1k/4c8cSzWOZYGyQTyrxVon0y2p5TWVH9+Dnic7HyStn6t1Gr08B7JST7t\nIgE/jIiHIuKi6n2Hpb4jc54B2vHM1MEyOJzs9bJbu712Plm9VtAt/eqBtsukeqTb8cAD+FrZS6OH\nt5+G9jklpXQ8sAD4RESc2v/BlP39r63zGkEG7ZLPDcDrgC5gG/DnQ+zbsplExCTgr4E/TCn9uv9j\nvlYaP7y3ADP7bc9k7z8h20ZKaVv1n/8O/A3ZX+ueiYhpABHxWuAXxa2wMINlUPvamVG9r+WllH6R\nqoCb6asA2iaTiBhPNri/kVL62+rdvlb6afTw3nOST0QcQHaSzx0N/p2lExEHRcTk6s8TgXcDa8my\nOK+623nA3w78DC1tsAzuAM6JiAMi4nXAHODBAtY35qqDabf/QfZagTbJJCICuAVYl1Ja0e8hXyv9\nDHeG5X5Jg5zk08jfWVKHAX+TvSYZB9yWUvpBRDwEfCsiLgA2AWcVt8TGi4jbgXcAh0bE08DngKsY\nIIOU0rqI+BawDngZ+Hj1nWhLGSCTy4HuiOgi+6v/z4DdJ8W1RSbAKcC5wKMRsbp63yW0+Wullifp\nSFIT8mvQJKkJObwlqQk5vCWpCTm8JakJObwlqQk5vCWpCTm8JakJObwlqQn9fxKBzNp4VS+ZAAAA\nAElFTkSuQmCC\n",
       "text": [
        "<matplotlib.figure.Figure at 0x7fb5af2bf7d0>"
       ]
      }
     ],
     "prompt_number": 27
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [],
     "language": "python",
     "metadata": {},
     "outputs": []
    }
   ],
   "metadata": {}
  }
 ]
}